Introducing NXtec: An Update to digitalMLPA Product Naming

At MRC Holland, we’re always evolving to meet the needs of our users. As part of this ongoing innovation, we are introducing NXtec, the new product line name for all currently available digitalMLPA assays. This change helps us clearly distinguish our current assays from future variants that may require different protocols or reagents.

What does this mean for you?

• The NXtec product line includes our existing digitalMLPA assays D001 Hereditary Cancer Panel 1, D006 Multiple Myeloma, D007 Acute Lymphoblastic Leukemia, all of which will have “NXtec” added to their product name in the near future.
• No changes to your current digitalMLPA assays — catalogue numbers, instructions for use, protocol, reagents, and performance remain the same.
• The name NXtec will provide clarity as we develop different types of digitalMLPA assays in the future.

Why the update?
As we continue to advance digitalMLPA technology, we’re working on new assay variants that will require different workflows. NXtec allows us to differentiate the current, established format from these new developments.

We’ll keep you informed as new updates are ready. For now, this is simply a small naming update to help keep things clear.